Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its abstract has been accepted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback